Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited. The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.
Obesity is a major modifiable risk factor for atrial fibrillation and contributes to AF pathophysiology through systemic inflammation, autonomic imbalance, and adverse cardiac remodeling, including increased epicardial and atrial fat. Although exercise and weight reduction have been shown to improve AF-related outcomes, robust long-term randomized evidence integrating exercise, dietary intervention, objective AF burden monitoring, and cardiac magnetic resonance imaging is lacking. MOVE-AF is a parallel-group, open-label randomized controlled trial enrolling 158 overweight or obese adults with symptomatic paroxysmal or persistent AF. Participants will be randomized 1:1 to receive either a tailored exercise and dietary lifestyle intervention plus usual care or usual care alone. The intervention consists of individualized guideline-based aerobic and resistance exercise combined with dietary counseling aimed at reducing body fat mass. Main outcomes include AF burden assessed using continuous ambulatory rhythm monitoring, AF symptom severity assessed using validated questionnaires, and cardiac and total body fat mass assessed by cardiac MRI and body composition analysis. Secondary outcomes include cardiorespiratory fitness, muscle strength, cardiac autonomic nervous system function, cardiac remodeling, healthcare utilization, cost-effectiveness, and genetic risk modification of intervention effects. The study is conducted in accordance with the Declaration of Helsinki and applicable regulatory requirements. All participants will provide written informed consent before enrollment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
158
A 12-month tailored lifestyle program combining individualized aerobic exercise, muscle strength training, and dietary counseling. The program includes home-based aerobic training 2-5 times per week, muscle strength training, group-based dietary intervention sessions, and motivational support. The intervention is added to standard clinical care for atrial fibrillation.
Participants receive standard clinical care for atrial fibrillation according to the guideline-based routine practice at participating hospitals. No structured exercise or dietary lifestyle intervention is provided.
Hospital Nova of Central Finland
Jyväskylä, Central Finland, Finland
RECRUITINGUniversity of Eastern Finland
Kuopio, Eastern Finland, Finland
NOT_YET_RECRUITINGKuopio University Hospital
Kuopio, Northern Savonia, Finland
NOT_YET_RECRUITINGTampere University Hospital
Tampere, Finland
NOT_YET_RECRUITINGAtrial Fibrillation Burden
Total atrial fibrillation burden measured by continuous rhythm monitoring over the intervention period. Unit of Measure: Percentage of time in atrial fibrillation (%)
Time frame: 12 months
Cardiac Fat Mass
Epicardial and pericardial fat volume measured by cardiac MRI. Unit of Measure: Milliliters (ml).
Time frame: 12 months
AF Symptom Severity
Symptom severity assessed using the Atrial Fibrillation Effect on Quality-of-Life Questionnaire (AFEQT). Unit of Measure: Score on a 0-100 scale. Interpretation: Higher scores indicate better AF-related quality of life (i.e., fewer or less severe symptoms).
Time frame: 12 months
Body Fat Mass
Total body fat mass assessed using a body composition analyzer. Unit of Measure: Kilograms (kg)
Time frame: 12 months
Six-Minute Walk Test (6MWT)
Functional exercise capacity assessed using the Six-Minute Walking Test (6MWT). Unit of Measure: Meters walked in 6 minutes. Interpretation: Higher values indicate better functional capacity.
Time frame: 12 months
AF-Related Quality of Life (AFEQT Overall Score)
AF-related quality of life assessed using the Atrial Fibrillation Effect on Quality-of-Life Questionnaire (AFEQT). Unit of Measure: Score (0-100). Interpretation: Higher scores indicate a better quality of life.
Time frame: 12 months
Cost-effectiveness analysis
Healthcare costs determined using patients' social security ID numbers to track specialized healthcare visits, imaging examinations, treatment days, AF treatments, and external service usage. Unit of Measure: Euro (€)
Time frame: 36 months
Left Atrial Volume
Left atrial volume measured by echocardiography. Unit of Measure: Milliliters (ml)
Time frame: 12 months
Cardiac autonomic nervous system function
Heart rate variability assessed using a standardized protocol with 2 minutes sitting followed by 3 minutes of standing. Unit of Measure: HRV parameters (ms)
Time frame: 12 months
Peak Oxygen Uptake (VO₂peak)
Cardiorespiratory fitness assessed using cardiopulmonary exercise testing (CPET). Unit of Measure: VO₂peak (ml/kg/min) Interpretation: Higher values indicate better cardiorespiratory fitness.
Time frame: 12 months
Left Atrial Volume Index
Left atrial volume indexed to body surface area by echocardiography. Unit of Measure: ml/m²
Time frame: 12 months
Left Atrial Strain
Left atrial strain measured by speckle-tracking echocardiography. Unit of Measure: Percentage (%)
Time frame: 12 months
Left Ventricular Ejection Fraction
Left ventricular systolic function assessed by echocardiography. Unit of Measure: Percentage (%)
Time frame: 12 months
E/e' Ratio
Left ventricular diastolic function assessed using transmitral inflow and tissue Doppler imaging. Unit of Measure: Unitless ratio
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.